RecallDepth
Class II Ongoing

Duloxetine Delayed-Release Capsules, USP, 60 mg, 1,000 Capsules per bottle, Rx Only, Manufactured by: Towa Pharmaceutical Europe, S.L., Martorelles, (Barcelona), Spain. Manufactured for: Quallent Pharmaceuticals Health LLC, Grand Cayman, Cayman Islands. NDC 82009-032-10

This recall is currently active, issued August 20, 2025. It was issued by Breckenridge Pharmaceutical, Inc..

Company
Breckenridge Pharmaceutical, Inc.
Recall Initiated
July 25, 2025
Posted
August 20, 2025
Recall Number
D-0580-2025
Voluntary / Mandated
Voluntary: Firm initiated
Quantity
1,856 bottles
Firm Location
Berkeley Heights, NJ, United States
Official Source
View on FDA website ↗

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.

Distribution

NJ, AZ, IN

Lot / Code Info

Lot 240539C, Exp 1/31/2027

More recalls by Breckenridge Pharmaceutical, Inc.

View all recalls by this company →

Other recent Class II Drug recalls